It is, however, of considerable interest that both the co-injection of oxytocin with raclopride (de la Mora et al., 2016) and the previous raclopride administration (Laszlo et al., 2020) prevented the oxytocin-induced anxiolytic effects, suggesting a possible interaction between the OXTR- and the D2R-mediated neurotransmission on the modulation of anxiety. The gene discussed is OXTR; the disease is Anxiety.